Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cincinnati Financial Corporation (CINF) vs Summit Therapeutics Inc (SMMT) Price & Performance

Cincinnati Financial CorporationTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Cincinnati Financial Corporation vs Summit Therapeutics Inc — how do they compare? Cincinnati Financial Corporation trades at $172.46 (market cap $26.58B), while Summit Therapeutics Inc trades at $15.18 (market cap $12.06B). The key difference: Cincinnati Financial Corporation is far larger — about 2.2× Summit Therapeutics Inc's market cap, and Cincinnati Financial Corporation pays a 2.17% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

CINFSMMT
Market Cap
$26.58B$12.06B
Sector
FinancialsHealth
52-Week High
$192.03$26.98
52-Week Low
$149.79$12.55
Enterprise Value
$25.71B$11.39B
Dividend Yield
2.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cincinnati Financial Corporation

Cincinnati Financial (CINF) trades at $172.87, down 0.57% on the day, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 earnings miss ($1.43 vs. $1.84 expected) but maintains robust revenue growth and profitability with a 23.84% net income margin. Cash flow trends show improvement, with 2025 net cash flow reaching $448 million. Analyst consensus remains positive with a $195 price target, though technical indicators suggest near-term pressure.

CINF presents a value opportunity with attractive valuation metrics (P/E 8.18, P/B 1.59) and consistent dividend growth. Key risks include catastrophe losses impacting underwriting results and commercial lines performance. The stock's current technical weakness may offer entry points for long-term investors seeking quality insurance exposure with strong ROE of 21.48%.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.

Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.

Returns comparison

Trailing returns across standard periods

About Cincinnati Financial Corporation

Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.

Read more on CINF

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT